← Back to Clinical Trials
Recruiting NCT06889454

NCT06889454 Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06889454
Status Recruiting
Phase
Sponsor Attikon Hospital
Condition PCOS
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2024-02-01
Primary Completion 2025-02-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 45 Years
Study Type OBSERVATIONAL
Interventions
GLP-1 receptor agonistOral contraceptiveMetformin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2024-02-01 with a primary completion date of 2025-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.

Eligibility Criteria

Inclusion Criteria: 1. Age \> 16 years old 2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following: * Clinical or biochemical hyperandrogenism * Anovulation or oligo-ovulation * Polycystic ovarian morphology (PCOM) 3. Absence of treatment for PCOS the last six months 4. Patients who have the ability to understand and sign the consent form. Exclusion Criteria: 1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \[17-OHP\]), Cushing syndrome, acromegaly 2. Treatment with contraceptive or metformin 3. Type 2 diabetes mellitus 4. Treatment for diabetes 5. Pregnancy 6. Lactation 7. Malignancy

Contact & Investigator

Central Contact

VAIA lAMBADIARI, Professor

✉ vlambad@otenet.gr

📞 2105831148

Frequently Asked Questions

Who can join the NCT06889454 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying PCOS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06889454 currently recruiting?

Yes, NCT06889454 is actively recruiting participants. Contact the research team at vlambad@otenet.gr for enrollment information.

Where is the NCT06889454 trial being conducted?

This trial is being conducted at Chaïdári, Greece.

Who is sponsoring the NCT06889454 clinical trial?

NCT06889454 is sponsored by Attikon Hospital. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology